Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mutant IDH1 Inhibitor Olutasidenib
Conditions
Mutant IDH1 Inhibitor Olutasidenib
Trial Timeline
Aug 29, 2024 → Jun 30, 2029
NCT ID
NCT06445959About Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine
Olutasidenib + Venetoclax + Decitabine + Decitabine/cedazuridine is a phase 1/2 stage product being developed by Rigel Pharmaceuticals for Mutant IDH1 Inhibitor Olutasidenib. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06445959. Target conditions include Mutant IDH1 Inhibitor Olutasidenib.
What happened to similar drugs?
0 of 4 similar drugs in Mutant IDH1 Inhibitor Olutasidenib were approved
Approved (0) Terminated (1) Active (3)
🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06445959 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Mutant IDH1 Inhibitor Olutasidenib